8-K: Xeris Biopharma Shareholders Affirm Board, Auditor, and Executive Pay at 2025 Annual Meeting

Xeris Biopharma Holdings, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting of Stockholders, including the election of Class I directors, ratification of its independent auditor, and approval of executive compensation.

Summary

• Xeris Biopharma Holdings, Inc. held its 2025 Annual Meeting of Stockholders on June 4, 2025.
• As of the record date, April 14, 2025, 156,384,578 shares of common stock were outstanding and entitled to vote.
• A quorum was present with 111,098,912 shares represented by proxy.
• Shareholders elected three Class I directors: BJ Bormann, James Brady, and Garheng Kong, to serve until the 2028 Annual Meeting.
• BJ Bormann received 57,050,196 'For' votes and 21,676,213 'Withhold' votes.
• James Brady received 76,465,887 'For' votes and 2,260,522 'Withhold' votes.
• Garheng Kong received 75,938,627 'For' votes and 2,787,782 'Withhold' votes.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 110,053,757 'For' votes.
• The advisory vote to approve Named Executive Officer compensation passed with 72,202,176 'For' votes.

Sentiment

Score: 7

Explanation: The document reports routine annual meeting results where all proposals passed, indicating stable corporate governance and shareholder alignment. There are no negative surprises or significant issues disclosed.

Positives

• All three Class I director nominees (BJ Bormann, James Brady, and Garheng Kong) were successfully elected by a plurality vote.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025 was overwhelmingly ratified by shareholders.
• Shareholders approved, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers, indicating general satisfaction with executive pay practices.

Negatives

• BJ Bormann received a notable number of 'Withhold' votes (21,676,213) compared to the other elected directors, though still elected.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This 8-K filing details the routine outcomes of an annual shareholder meeting, which is a standard corporate governance event for publicly traded companies in the biopharmaceutical industry. The results indicate typical shareholder engagement and approval of management and governance proposals.

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmed their votes on key governance matters, including board composition, auditor selection, and executive compensation.
• Management: Received shareholder endorsement for the nominated directors and executive compensation plan, providing a clear mandate for ongoing operations.

Next Steps

• The elected Class I directors (BJ Bormann, James Brady, and Garheng Kong) will serve until the 2028 Annual Meeting of Stockholders.
• Ernst & Young LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

Keywords

Xeris Biopharma, XERS, Annual Meeting, Shareholder Vote, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, 8-K